• Je něco špatně v tomto záznamu ?

Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study

T. Chitnis, DL. Arnold, P. Quartier, M. Chirieac, W. Hu, S. Jurgensen, EK. Havrdova

. 2025 ; 31 (1) : 23-35. [pub] 20241201

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010453

BACKGROUND: Limited licensed medications are available for multiple sclerosis (MS) in pediatric patients. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of alemtuzumab in pediatric patients with relapsing-remitting multiple sclerosis (RRMS) and disease activity on prior disease-modifying therapies (DMTs). METHODS: LemKids was a multicenter, multinational, single-arm, open-label, switch (from ongoing DMT to alemtuzumab treatment) study in pediatric RRMS patients (aged 10-<18 years), with disease activity on DMT. The primary endpoint was a comparison of the number of new/enlarging T2 lesions on the magnetic resonance imaging of the brain between the prior-DMT period and alemtuzumab treatment. RESULTS: This study was prematurely terminated due to low enrollment and an European Medicines Agency Article-20 pharmacovigilance review of alemtuzumab in adult RRMS. Of 46 screened patients, 16 were enrolled; 12 completed prior-DMT treatment period; 11 received alemtuzumab of whom 7 completed treatment. Patients on alemtuzumab developed fewer new/enlarging T2 lesions compared with prior-DMT (7 vs 178, relative risk (95% confidence interval): 0.04 (0.01-0.14)). No significant pharmacodynamic changes or safety concerns were noted in this limited dataset. CONCLUSION: Alemtuzumab treatment was associated with a low number of new/enlarging T2 lesions in pediatric patients with RRMS and was safe and well tolerated in seven patients during infusion and the initial 4 months.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010453
003      
CZ-PrNML
005      
20250429134910.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/13524585241295554 $2 doi
035    __
$a (PubMed)39618059
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Chitnis, Tanuja $u Department of Pediatric Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA $1 https://orcid.org/0000000298974422
245    10
$a Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study / $c T. Chitnis, DL. Arnold, P. Quartier, M. Chirieac, W. Hu, S. Jurgensen, EK. Havrdova
520    9_
$a BACKGROUND: Limited licensed medications are available for multiple sclerosis (MS) in pediatric patients. OBJECTIVE: To evaluate the efficacy, safety, and tolerability of alemtuzumab in pediatric patients with relapsing-remitting multiple sclerosis (RRMS) and disease activity on prior disease-modifying therapies (DMTs). METHODS: LemKids was a multicenter, multinational, single-arm, open-label, switch (from ongoing DMT to alemtuzumab treatment) study in pediatric RRMS patients (aged 10-<18 years), with disease activity on DMT. The primary endpoint was a comparison of the number of new/enlarging T2 lesions on the magnetic resonance imaging of the brain between the prior-DMT period and alemtuzumab treatment. RESULTS: This study was prematurely terminated due to low enrollment and an European Medicines Agency Article-20 pharmacovigilance review of alemtuzumab in adult RRMS. Of 46 screened patients, 16 were enrolled; 12 completed prior-DMT treatment period; 11 received alemtuzumab of whom 7 completed treatment. Patients on alemtuzumab developed fewer new/enlarging T2 lesions compared with prior-DMT (7 vs 178, relative risk (95% confidence interval): 0.04 (0.01-0.14)). No significant pharmacodynamic changes or safety concerns were noted in this limited dataset. CONCLUSION: Alemtuzumab treatment was associated with a low number of new/enlarging T2 lesions in pediatric patients with RRMS and was safe and well tolerated in seven patients during infusion and the initial 4 months.
650    _2
$a lidé $7 D006801
650    12
$a alemtuzumab $x škodlivé účinky $7 D000074323
650    12
$a relabující-remitující roztroušená skleróza $x farmakoterapie $x diagnostické zobrazování $7 D020529
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mladiství $7 D000293
650    12
$a imunologické faktory $x škodlivé účinky $x aplikace a dávkování $7 D007155
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Arnold, Douglas L $u McGill University, Montreal, QC, Canada; NeuroRx Research, Montreal, QC, Canada $1 https://orcid.org/0000000342660106
700    1_
$a Quartier, Pierre $u Université Paris-Cité, Paris, France $u RAISE Rare Disease Reference Centre, Pediatric Immunology-Hematology and Rheumatology Unit, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
700    1_
$a Chirieac, Magdalena $u Sanofi, Cambridge, MA, USA
700    1_
$a Hu, Wenruo $u Sanofi, Beijing, China
700    1_
$a Jurgensen, Stephanie $u Sanofi, Bridgewater, NJ, USA
700    1_
$a Havrdova, Eva K $u Department of Neurology, First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00006389 $t Multiple sclerosis $x 1477-0970 $g Roč. 31, č. 1 (2025), s. 23-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39618059 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134905 $b ABA008
999    __
$a ok $b bmc $g 2311670 $s 1247534
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 31 $c 1 $d 23-35 $e 20241201 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace